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Abstract
Frizzled receptors mediate Wnt ligand signalling, which is crucially involved in regulating tissue development
and differentiation, and is often deregulated in cancer. In this study, we found that the gene encoding the
Wnt receptor frizzled 6 (FZD6) is frequently amplified in breast cancer, with an increased incidence in the
triple-negative breast cancer (TNBC) subtype. Ablation of FZD6 expression in mammary cancer cell lines: (1)
inhibited motility and invasion; (2) induced a more symmetrical shape of organoid three-dimensional cultures;
and (3) inhibited bone and liver metastasis in vivo. Mechanistically, FZD6 signalling is required for the assembly of
the fibronectin matrix, interfering with the organization of the actin cytoskeleton. Ectopic delivery of fibronectin
in FZD6-depleted, triple-negative MDA-MB-231 cells rearranged the actin cytoskeleton and restored epidermal
growth factor-mediated invasion. In patients with localized, lymph node-negative (early) breast cancer, positivity
of tumour cells for FZD6 protein identified patients with reduced distant relapse-free survival. Multivariate analysis
indicated an independent prognostic significance of FZD6 expression in TNBC tumours, predicting distant, but not
local, relapse. We conclude that the FZD6–fibronectin actin axis identified in our study could be exploited for
drug development in highly metastatic forms of breast cancer, such as TNBC.
© 2016 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain
and Ireland.
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Introduction
Breast cancer is the most frequent malignancy in
women, accounting for >200 000 new cases per year in
the USA and 350 000 in Europe [1–3]. A decline in the
mortality resulting from breast cancer has recently been
documented, most likely as the result of the combination
of an increase in public awareness, the implementation
of screening programnes, and advances in adjuvant
treatments [1,3]. Screening programmes have increased
the detection of early-stage, node-negative tumours
with a low risk of recurrence. Approximately 70–80%
of these patients are cured by local or regional treat-
ment, often in combination with adjuvant systemic
therapy, which significantly reduces the risk of recur-
rence [4]. Risk-group discrimination is achieved by
assessing prognostic factors, such as tumour size and
grade, hormone receptor status, age, or menopausal
© 2016 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and
reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
FZD6 is frequently amplified in breast cancer 351
status. Despite the majority of patients without nodal
involvement receiving some form of adjuvant treatment,
approximately one-third will experience recurrence
[5,6].
The Wnt pathway is an important regulator of tissue
development in different organ systems [7–9]. There
are 10 Wnt receptors in mammalian cells; called friz-
zled (e.g. FZD1–FZD10), they activate a canonical
or a non-canonical pathway, depending on the ligand
and the cell type. Frizzled receptors, including FZD7,
FZD3, and FZD2, andWnt ligands, such as WNT3a and
WNT5a/b, have been shown to play an important role in
promoting aggressive behaviour, instigating the growth
of breast cancer cells [10–13] and cancer stem cells
in the metastatic niche [10]. The possible involvement
of FZD6 in transformation is emerging, because this
receptor is overexpressed in several cancers, including
hepatocarcinoma, colon cancer, prostate cancer, and
leukaemia [14–17]. Our own group has revealed that
FZD6 expression is associated with drug resistance
and increased invasiveness in neuroblastoma, marking
cancer-initiating cells [18]. In the present study, we
examined whether FZD6 activity is required for breast
cancer cell growth, motility and metastasis in vitro and
in vivo.
Materials and methods
Patients and tissues
The study included 352 primary infiltrating breast can-
cers from N0 and T1/T2 tumours, diagnosed between
1985 and 2003 at the Regina Elena National Cancer
Institute, Rome, Italy, and presenting primary unilateral
breast carcinoma. The study was reviewed and approved
by the ethics committee of the Regina Elena National
Cancer Institute, and written informed consent was
obtained from all patients. Patient and tumour char-
acteristics are summarized in supplementary material,
Table S1. All patients received radiation therapy, 138
patients received hormonal therapy and 140 patients
were treated with adjuvant chemotherapy (followed
or not by hormonal therapy) and are members of the
oestrogen-receptor (ER)-positive cohort. Patients with
HER2-positive tumours did not receive trastuzumab,
because it was not used in breast tumour therapy
in the study period. Follow-up data were obtained
from institutional records or by the referring physi-
cians. The median follow-up was 80months (range
6–298months). During follow-up, 32 patients (9.1%)
developed a local recurrence, and distant metastases
were observed in 54 cases (15.3%).
Cell culture
The cell lines used were kindly provided by P.
Marra [King’s College London (KCL)] and R.F.
Newbold (Brunel University): BT474 – luminal-
like metastatic ductal carcinoma; MDA-MB-231 –
basal-like metastatic adenocarcinoma; MDA-MB-
436 – basal-like adenocarcinoma; HCC1143 – basal-
like ductal carcinoma; HEK FT293 - human embryonic
kidney cells; MCF7 – luminal-like metastatic adeno-
carcinoma; SK-BR-3 – basal-like adenocarcinoma;
T47D –ductal adenocarcinoma; and BT20 – basal-like
adenocarcinoma. All cell lines had been indepen-
dently validated by short tandem repeat genotyping.
MDA-MB-231, HCC1143 and MDA-MD-436 cells
were grown in RPMI medium (Sigma Aldrich, St
Louis, MO, USA) 1mM in sodium pyruvate (Gibco,
ThermoFisher Scientific, Pittsburgh, PA, USA), supple-
mented with 10% fetal bovine serum (FBS) (Gibco).
HEK-FT293, MCF7 and SK-BR-3 cells were grown in
Dulbecco’s modified Eagle’s medium (DMEM) (Sigma)
1mM in sodium pyruvate, supplemented with 10% FBS.
BT20 and BT474 cells were grown in a mixture of 50%
DMEM and 50% Ham’s F12, supplemented with 10%
FBS. Cells were maintained at 37 ∘C in a humidified
atmosphere with 5% CO2. Human mammary epithelial
cells (HMECs) were cultured as described previously
[19].
MTS assay
The reagent 3-(4,5-dimethylthiazol-2-yl)-5-(3-car
boxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium
(MTS) (Promega, Madison, WI, USA) was added to cell
cultures in 96-well plates, and then incubated at 37 ∘C
for 2–4 h before reading of the absorbance at 490 nm
with a plate reader (Bio-Rad, Hercules, CA, USA).
Cell invasion assay
Between 30 000 and 180 000 cells were seeded in 500 μl
of medium without serum, and placed in the upper
chamber of Matrigel-coated invasion chambers (Becton
Dickinson, Franklin Lakes, NJ, USA). After 22 h, the
membrane was removed from the insert with a scalpel,
stained with crystal violet, and placed on a glass slide.
Pictures of the membrane were taken with a camera con-
nected to a microscope (Zeiss axioscope 2, Oberkochen,
Germany), and the number of cells invading theMatrigel
was determined with ImageJ software.
Plasmid construction
RNA was extracted from MDA-MB-231 cells, and
reverse-transcribed with an RNA-to-cDNAKit (Applied
Biosystems, Foster City, CA, USA). The FZD6 cDNA
was polymerase chain reaction (PCR)-amplified with
the primers CGCGGGTACCAGGAATTTGAAGAA
AATGGAAATG (forward) and GCGATCTAGAGT
TCTTCAAGTATCTGAATGACAACC (reverse), con-
taining a Kpn1 and an Xba1 restriction site, respectively.
The PCR product was cut with Kpn1 and Xba1 restric-
tion enzymes, and cloned into the expression vector
pcDNA3.1 (Invitrogen, Carlsbad, CA, USA).
Cell motility assay
Cells (3.8× 105) were seeded into bipartite chambers
for live imaging (Fisher, Hampton, NH, USA), and
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allowed to grow for 24 h in 1ml of complete medium.
The medium was then replaced with 2ml of Leibovitz’s
L-15 medium (Gibco), and the cells were placed back
in the incubator for 4 h. The cell monolayers were then
wounded with a sterile pipette tip and placed in a live
imaging microscope (Nikon Eclipse Ti, Tokyo, JP). At
least four different areas of each wound were pho-
tographed every 30min for 24 h. Cell trajectories were
tracked and path lengths measured over a period of 16 h
with the image analysis software NIS-Elements (Nikon).
The average speed of a minimum of 10 cells was scored
in four areas of each wound analysed.
Orthotopic transplantations in immunodeficient
mice
NOD scid gamma (NSG) mice were purchased from
the Jackson Laboratory, Bar Harbour, ME, USA, and
bred in the animal facility of Aging Research Centre,
G. D’Annunzio University, Chieti. Animal care and
experimental procedures were approved by the Ethics
Committee for Animal Experimentation of the institute,
according to the Italian law. Eight-week-old female
mice (10 mice per group) were injected unilaterally
with 3.5× 106 cells into the fourth mammary fat pad.
Tumour growth was monitored biweekly with callipers
up to 96 days or until tumours reached 0.3 cm3 in vol-
ume. Tumour volume was calculated as 0.5× d12 × d2,
where d1 and d2 are the smaller and larger diameters,
respectively. Primary tumours and organs were fixed
in 10% neutral buffered formalin, paraffin-embedded,
sectioned, and stained with haematoxylin and eosin
(H&E). Slides were evaluated independently by two
pathologists. To quantify microscopic metastases, livers
were cut transversally into 2.0-mm-thick parallel slabs
starting from a random position, resulting in 8–10
slabs. Semiquantitative evaluation was performed, with
each sample being attributed a value from 1 to 4, based
on the number and size of metastases; 1 was attributed
to organs with a few small metastases, and 4 to organs
with numerous large metastases. Fisher’s exact test was
used to compare differences in metastatic spread.
Glutathione-S-transferase (GST) pull-down and
western blot analysis
Western blot analysis was carried out as described
previously [18]. Total active Rho was quantified with
a pull-down/western blotting detection kit, according
to the manufacturer’s instructions (Thermofisher, Pitts-
burgh, PA, USA). The primary antibodies used were:
anti-FZD6 (D16E5; dilution 1:1000; Cell Signaling,
Boston, MA); anti-β-actin (I-19; dilution 1:1000; Santa
Cruz, Dallas, TX, USA); and anti-glyceraldehyde-
3-phosphate dehydrogenase (AB8245; dilution 1:1000;
Abcam, Cambridge, UK).
Bioinformatic analysis
R version 3.1.0 (2014-04-10) was used for all analy-
ses and diagrammatic representation of data. Gene
ontology (GO) enrichment was performed with
ConsensusPathDB-human enrichment tools [20,21],
and a dendrogram was created with QuickGO [22]. All
p-values reported in boxplots were determined with a
two-sided Wilcoxon rank sum test, and adjusted for
multiple testing by use of the false discovery rate [23].
Reverse transcription quantitative PCR (RT-qPCR
Total cellular RNA was extracted and reverse-
transcribed as described previously [24].
KCL and Molecular Taxonomy of Breast Cancer
International Consortium (METABRIC) data
A detailed description of the KCL data andMETABRIC
data, such as sample demographics and bioinformatics
analyses, has been published previously [25–27]. A
diagram depicting the studies fromwhich the samples of
the KCL cohort used in this study were derived is shown
in supplementary material, Figure S1.
Immunohistochemistry
Tissue microarrays were constructed by extracting
2-mm-diameter cores of histologically confirmed inva-
sive breast carcinoma areas, as previously described
[28]. After antigen retrieval (microwave treatment
at 750W for 10min in 10mM sodium citrate buffer,
pH 6.0), 5-μm sections were incubated overnight at
4 ∘C with the anti-FZD6 antibody (Novus Biological,
Littleton, CO, USA) at 1:100 dilution. The anti-rabbit
EnVision kit (K4003; Dako, Glostrup, Denmark) was
used for signal amplification. In control sections,
the specific primary antibody was replaced with
non-immune serum. Seventy-one of 352 (20.2%) cases
showed positive staining for FZD6, and the percentages
of tumour cells positive in each sample ranged from 2 to
85% [mean: 23.8± 2.5 standard error (SE)]. Positivity
for FZD6 in each subtype was as follows: luminal
A-like, 21.1%; luminal B-like (HER2-negative), 22.0%;
luminal B-like (HER2-positive), 15.2%; HER2 posi-
tive (non-luminal), 23.8%; and triple-negative (ductal),
14.9%. The following antibodies were used for the iden-
tification of tumour subtypes, as previously reported
[29]: the anti-ER-α monoclonal antibody (mAb) 6F11
(1:50; Novocastra, Leica Biosystems, Newcastle upon
Tyne, UK), the anti-progesterone receptor (PgR) mAb
1A6 (1:40; Novocastra, Leica Biosystems), and the
anti-Ki67 mAb MIB-1 (1:75; Dako, Ely, UK). HER2
was detected with the Herceptest kit, and the slides were
stained according to the manufacturer’s instructions
(Dako, Ely, UK). Immunohistochemical analysis was
performed by two pathologists (M.P. and R.L.) by con-
sensus, without knowledge of the clinicopathological
information.
ER, PgR and Ki67 expression were dichotomized
according to the St Gallen criteria [30]. HER2 mem-
branous staining was scored with the Herceptest kit,
and classified as positive if the intensity was scored as
3+, with ?30% of cells showing complete membrane
© 2016 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2017; 241: 350–361
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staining [31]. The relationships between FZD6 expres-
sion and clinicopathological parameters were assessed
with Pearson’s χ2 or Fisher’s exact test, as appropriate.
Kaplan–Meier plots were used to illustrate the survival
in specified cohorts, and the log-rank test was used to test
for equality of survival curves. The association of FZD6
expression with outcome, adjusted for other prognostic
factors, was tested by multivariate analysis (Cox’s pro-
portional hazards model). The following covariates were
included in the multivariate disease-free survival (DFS)
models: tumour size and grade, and ER, PgR, Ki67,
HER2 and FZD6 status. Appropriateness of the propor-
tional hazard assumption was assessed by plotting the
log cumulative hazard functions over time and checking
for parallelism. SPSS Version 15.0 (SPSS, Chicago, IL,
USA) was used throughout, and p< 0.05 was considered
to be statistically significant.
Results
FZD6 is frequently amplified and overexpressed in
triple-negative breast cancer (TNBC)
Given the importance of Wnt signalling in breast can-
cer, we systematically analysed gene copy number
variations (CNVs) and expression of the 10 known Wnt
receptor genes (FZD1 to FZD10) in the Sanger Institute
Cosmic repository [32]. Frizzled receptor genes are
only marginally altered in breast cancer as compared
with normal tissue, with the exception of FZD6. Indeed,
19.11% of breast samples showed FZD6 copy number
gains and 18.71% gene overexpression quantified as
z-score (supplementary material, Table S2). In com-
parison, FZD7 and FZD2, which have been previously
implicated in aggressive breast cancer [12,13], were
overexpressed only in 4% of tumours, without copy
number gains (supplementary material, Table S2).
Bioinformatic analysis with the METABRIC database
[33] indicated that FZD6 is amplified or gained in 73.2%
of breast cancers (supplementary material, Figure S2A).
Notably, FZD6 copy number increase was more fre-
quent in triple-negative (87.1%) than in ER-positive
(72%) cases (χ2 11.0493; p= 0.000887). Increased
expression levels of FZD6 were particularly observed in
tumour samples containing the amplification, suggest-
ing that this could drive gene expression in some breast
carcinomas (supplementary material, Figure S2A).
To corroborate these findings, we assessed the gene
expression and copy number data from a primary breast
cancer cohort enriched for triple-negative cases col-
lected at KCL (supplementary material, Figure S1)
[25,27]. The KCL cohort confirmed that FZD6 CNVs
were common in breast cancer (81.1% cases with
gains or amplification) and that there was an increased
incidence of FZD6 copy number gain and amplifi-
cation in triple-negative (88.1%) as compared with
non-triple-negative (61.7%) (χ2 13.7129; p= 0.000213)
or HER2-positive (63.1%) (χ2 6.9591, p= 0.0083)
cases, explaining the increased gene expression in this
subtype (Figure 1A–C; supplementary material, Figure
S2B). Expression of the non-canonical FZD6 ligands
WNT11 and WNT5B, but not of the canonical WNT1
and WNT3A, was also increased in triple-negative
samples as compared with other subtypes, suggesting
that a Wnt non-canonical signalling axis could be
activated downstream of FZD6 in aggressive forms of
breast cancer (Figure 1D–G). Overall, the bioinfor-
matic analyses and our previous study, in which we
demonstrated that FZD6 promotes metastasis and a stem
cell-like phenotype in neuroblastoma [18], prompted
us to further investigate the role of this receptor in the
aggressive behaviour of mammary cancer cells.
FZD6 regulates motility, invasion
and three-dimensional (3D) growth, but not
proliferation, of breast cancer cell lines
To assessFZD6 expression in breast cancer cell lines, we
prepared total cellular RNAs and protein lysates from
a panel of breast cancer cell lines representative of the
different molecular subtypes. Normal HMECs and their
hTERT-immortalized counterparts were also used for
comparison. RT-qPCR and ImageStream analyses show
that expression of FZD6 was higher in immortalized
HMECs than in normal human epithelial cells (supple-
mentary material, Figure S3A, C). Among breast can-
cer cell lines, basal-like cells generally expressed more
FZD6 than luminal ones, although the samples were too
small to determine statistical significance. This trend
corroborates the hypothesis that frequent FZD6 ampli-
fication in basal cells might induce high levels of FZD6
expression. The difference in protein expression was
not, however, reflected at the RNA level (supplementary
material, Figure S3A, B). We next assessed the expres-
sion of FZD6 on cell surfaces by using flow cytome-
try and ImageStream analysis. With the exception of
MB-MDA-436, all breast cancer cell lines expressed
FZD6 on the plasmamembrane, although the mean fluo-
rescence intensity and percentage of positive cells varied
among the different samples (supplementary material,
Figure S3D, E).
To study the physiological role of FZD6 in breast
cancer, we investigated its role in cell motility, as
non-canonical Wnt signalling is known to regulate
this cell function. First, we ectopically overexpressed
a FZD6 cDNA into luminal SK-BR-3 and T47D
cells, in which expression of FZD6 protein is low
(supplementary material, Figure S3B; Figure 2A).
Live cell imaging indicated that overexpression of
FZD6 caused a significant increase in SK-BR-3 and
T47D cell motility (Figure 2B). Accordingly, deple-
tion of endogenous FZD6 with short-hairpin RNAs
(shRNAs) significantly reduced motility of FZD6high
triple-negative MDA-MB-231 cells in wound healing
assays (Figure 2C). Verification of FZD6 mRNA and
protein depletion is shown in supplementary material,
Figure S4A.
We next assessed the role of FZD6 in the proliferation
and invasion of breast cancer cell lines by using transient
© 2016 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2017; 241: 350–361
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Figure 1. Analysis of CNV and expression of the FZD6 and WNT genes in breast cancer samples from KCL data. (A) Distribution of
CNVs, as defined by ASCAT (http://www.pnas.org/content/107/39/16910.long), of FZD6 in breast cancer subtypes defined according to
immunohistochemistry (IHC) criteria. (B) Box plot analysis showing mRNA expression levels of FZD6 in the different immunohistochemical
subtypes. (C) Box plot analysis showing expression of FZD6 in PAM50 subtypes [49]. (D–G) Box plot analyses of WNT11 (D) WNT5B (E)
WNT1 (F) and WNT3A (G) expression in PAM50 subtypes. CN, copy number; LumA, luminal A; LumB, luminal B.
and stable RNA interference approaches. Depletion of
FZD6 did not perturb the metabolism/proliferation of
breast cancer cells, with the exception of the HCC1143
cell line (Figure 3A). Cell cycle profiles and sub-G1
DNA content were unchanged, suggesting that cell
proliferation and apoptosis are not modified in the
absence of the receptor (data not shown). In contrast,
there was a significant reduction in invasive potential
after depletion of FZD6. The inhibitory effect of the
small interfering RNAs (siRNAs) was proportional
to the level of FZD6 knockdown, and the oligonu-
cleotides were unable to modify the invasive potential
of MDA-MB-436 cells with no membrane expression
of FZD6, which should rule out potential off-target
effects of the siRNAs (Figure 3B). The chosen siRNAs
were confirmed to cause strong knockdown of FZD6
mRNA expression (supplementary material, Figure
S4B). Verification of surface depletion of FZD6 protein
in the MD-MB-231 cell line by ImageStream analysis
is shown in supplementary material, Figure S4C. These
results were further validated with the MDA-MB-231
cell lines with permanent FZD6 knockdown caused by
shRNAs (Figure 3A, B).
Organoid 3D cultures in Matrigel have been used to
determine the degree of transformation of breast can-
cer cells [34]. In the absence of FZD6, the symmetri-
cal shape of breast cancer acini forming in the Matrigel
structure was significantly increased (supplementary
© 2016 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2017; 241: 350–361
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Figure 2. Cell motility assays. (A) Western blot analysis showing FZD6 protein levels in SK-BR-3 and T47D breast cancer cell lines following
transient transfection of CMV-FZD6 or CMV-control expression vectors. MDA-MB-231 cell lysates were used as a positive FZD6 control.
(B) Cells were placed in a live imaging system and filmed for 24 h. The motility of green fluorescent protein-positive (i.e. transfected) cells
was calculated, and is plotted on the y-axis. (C) MDA-MB-231 cells infected with lentiviruses containing control (scrambled) or FZD6 (Sh2)
shRNA were grown as a monolayer, and then scratched with a pipette tip. Pictures were taken at the indicated times, and show the closure
of the wound in control (scrambled) but not in FZD6-downregulated (Sh2-FZD6) cells. Quantification of the experiment is shown in the
bar plot. Error bars indicate SEs, and asterisks indicate statistical significance (Student’s t-test).
material, Figure S5A–D). This experiment indicates
that the increased expression of the receptor in can-
cer induces disorganized 3D growth, promoting a more
aggressive phenotype. Notably, forced expression of
FZD6 in non-transformed MCF10A mammary epithe-
lial cells modified 3D growth, inducing larger and less
circular acini, validating the hypothesis that the receptor
is a mammary protooncogene (Figure S5E–G). FZD6
overexpression in MCF10A cells was confirmed by
RT-qPCR (supplementary material, Figure S4D).
FZD6 regulates the metastatic process in vivo
To assess the role of FZD6 in growth and metastasis
of breast cancer cells in vivo, we transplanted highly
metastatic MDA-MB-231 cells into the mammary fat
pads of immunocompromised NSG mice. In this model,
breast cancer cells invade different organs, including the
lungs, liver, heart, and bones, which are also sites for
metastasis in humans. Despite the fact that growth of
FZD6-negative cells was slightly delayed in comparison
with control cells, at the end of the experiment the size
of the primary tumour masses was similar in the two
groups, indicating that FZD6 is largely dispensable
for breast cancer cell proliferation in vivo (Figure 4A).
However, there was a clear difference in the metastatic
patterns. Specifically, we detected significantly fewer
mice with bone metastases and a non-significant reduc-
tion in mice with heart and liver metastases when they
were injected with FZD6-depleted cells with respect to
© 2016 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2017; 241: 350–361
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Figure 3. Effects of siRNA or shRNA FZD6 knockdown in breast cancer cell lines. (A) MTS assay showing the metabolic activity, expressed as
optical density (OD) units, of the different breast cancer cell lines in the presence of control or FZD6 siRNAs. MDA-MB-231 cells were stably
transfected with control (scrambled) or FZD6 shRNAs (Sh1 and Sh2). Error bars indicate SEs, and asterisks indicate statistical significance
(Student’s t-test, n= 3). (B) In vitro invasion assays of the breast cancer cell lines transfected as described in (A). Error bars indicate SEs,
and asterisks indicate statistical significance (Student’s t-test, n= 3). NS, not significant.
control cell-injected mice (Figure 4B; supplementary
material, Table S3A). The difference in metastatic
growth in the liver has been further highlighted by
the use of a score system that takes into account
the number and size of metastases (supplementary
material, Table S3B). Immunohistochemical analysis
showed that FZD6 expression was reactivated in all
metastases originating from cells infected with the
FZD6 shRNA-targeting retrovirus, probably because of
silencing or loss of the shRNA vector in the absence
of selective pressure (an example is shown in supple-
mentary material, Figure S6A). This should explain
why the difference in metastatic potential between
FZD6-expressing and FZD6-non-expressing cells
appeared to be attenuated in vivo as compared with
the in vitro assays. Overall, these results support the
hypothesis that FZD6 is dispensable for proliferation,
but is required for motility, invasion and organ tropism
of TNBC cells.
FZD6 signalling regulates fibronectin deposition
and assembly of the actin cytoskeleton
in MDA-MB-231 cells
We next investigated whether FZD6 could be involved in
the regulation of the extracellular matrix, and fibronectin
in particular. Different studies have demonstrated that
the Wnt–planar cell polarity non-canonical pathway
is essential for deposition of the extracellular matrix
and organization of fibrillar fibronectin during frog
gastrulation [35,36]. It has also been shown that growth
factors such as epidermal growth factor (EGF) induce
motility and invasion by regulating the assembly of
fibronectin at the surfaces of MDA-MB-231 breast
cancer cells [37]. We were thus interested in determin-
ing whether FZD6 could regulate MDA-MB-231 cell
invasion via reorganization of the fibronectin matrix.
To this end, we quantified fibronectin in FZD6-positive
and FZD6-negative cells. Detection of fibronectin by
immunofluorescence analysis showed that there was
a reduction in the number of fibronectin fibres after
FZD6 knockdown (Figure 5A, B). By using confocal
microscopy, we ascertained that fibronectin was dis-
persed in control cells, whereas it was concentrated in
dots or blobs similar to endosomes in FZD6-depleted
cells (Figure 5C). Extracellular polymerization of
fibronectin can inhibit the assembly of stress fibres
formed by F-actin inside the cell [38]. Furthermore, it
has been shown that inhibition of FZD7 and FZD4 sig-
nalling promotes cell spreading and stress fibre forma-
tion [39]. In the absence of FZD6, F-actin is organized
in long fibres running throughout the cell. In contrast, in
control cells F-actin fibres are thinner and concentrated
in discrete areas in the proximity of the plasma mem-
brane (Figure 5C). Exogenous delivery of fibronectin
rescues the actin phenotype, indicating that a functional
pathway exists linking FZD6 signalling to fibronectin
and actin (Figure 5D). To determine whether FZD6
controls invasion by regulating fibronectin deposition,
we plated FZD6 wild-type and knockout cell lines in
invasion chambers, and used EGF as a chemoattractant.
Notably, exogenous supplementation of fibronectin par-
tially restored the invasive potential of FDZ6-depleted
cells (Figure 5E), demonstrating that there is a mech-
anistic link connecting FZD6 signalling to fibronectin
and metastatic activity. It has been reported that friz-
zled receptors modulate the actin cytoskeleton via
activation of the non-canonical pathway and Rho
signalling in ovarian cancer cells [40]. Indeed, there
was less active Rho in FZD6-depleted cells, suggest-
ing that FZD6 modulates the actin cytoskeleton via
non-canonical Wnt signalling (Figure 5F, G). Finally,
we carried out a pathway over-representation analysis
in the KCL cohort. This identified over-represented GO
terms such as cytoskeletal organization, intermediate
filament-based processes and cell polarity within the
200 most FZD6-coexpressed genes, further supporting
our hypothesis that a major function of FZD6 signalling
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Figure 4. Orthotopic xenotransplantation of MB-MDA-231 cells
with or without FZD6 expression in NSG mice. (A) MB-MDA-231
cells infected with a lentivirus containing FZD6 (Sh1) or control
(scrambled) shRNAs were injected into the fat pads of immunocom-
promised NSG mice. Growth of the primary tumour was measured
two times per week with callipers. Error bars indicate SEs. (B) H&E
staining of representative sections showing metastatic dissemina-
tion. Scale bars: 100 μm.
is to regulate cancer cell structure and movements
(supplementary material, Figure S6B).
Prognostic significance of FZD6 expression in breast
cancer patients
We carried out immunohistochemical analysis with an
FZD6 antibody in a retrospective Italian cohort of 352
patients with node-negative early breast cancer (T1–T2,
NO) (supplementary material, Table S1). Cytoplasmic
and membranous staining was present in 20.2% of the
specimens (Figure 6A–D). When we considered the
whole patient cohort, FZD6 expression was not signif-
icantly associated with clinical features (supplementary
material, Table S4). However, Kaplan–Meier analysis
indicated that FZD6 expression was significantly asso-
ciated with reduced distant relapse-free survival (DRFS)
in the TNBC patient subgroup, whereas there was no
significant association with other subtypes (Figure 6E
and data not shown). In multivariate analysis, FZD6
expression was an independent prognostic indicator for
DFS and DRFS in triple-negative cases [respectively:
hazard ratio (HR) 5.7, 95% confidence interval (CI)
1.5–22.9, p= 0.011; and HR 6.8, 95% CI 1.2–37.4,
p= 0.027] (supplementary material, Table S5). Tumour
grade was the only independent factor influencing DFS
and DRFS in the whole patient population (supplemen-
tary material, Table S6). The prognostic value of FZD6
expression was investigated at the mRNA level with
the aid of an online survival analysis tool to rapidly
assess the effect of gene expression on breast cancer
prognosis [41]. Consistent with the immunohistochem-
ical analysis, high FZD6 expression in tumours from
lymph node-negative TNBC patients predicts a signifi-
cant risk of distant metastatic recurrence (HR 2.35, 95%
CI 1.16-4.75, p= 0.014) (Figure 6F).
Discussion
At least four main molecular subclasses of breast cancer
have been identified so far: luminal A, luminal B,
HER2-positive, and basal-like, which largely over-
laps with the clinically defined TNBC forms. These
show significant differences in incidence, survival, and
response to therapy [42]. Accurate molecular pheno-
typing of breast cancer is thought to be key for the
identification of patient groups in need of more specific,
personalized care.
In this study, we assessed expression of FZD6 in pub-
lic databases, a cohort of breast cancer cases enriched
for the TNBC subtype collected in Guy’s Hospital,
and a retrospective Italian cohort of 352 patients with
node-negative early breast cancer (classified as T1–T2,
N0). The main finding of this analysis is that the
genomic region encompassing FZD6, but not other
frizzled receptors, is amplified with high frequency in
breast cancer. We have also observed an increased inci-
dence of FZD6 gains and augmented gene expression in
triple-negative cases. However, other cancer subtypes,
such as ER-positive breast cancers, show amplification
and overexpression of FZD6 in the analysed databases.
Gene amplification is almost certainly one driver of high
expression of FZD6 in breast cancer. In multivariate
analysis, expression of FZD6 protein was significantly
associatedwith lowermetastasis-free survival in patients
with TNBC.
Previous studies have highlighted the important role
of Wnt signalling in breast cancer. Wnt ligands such
as WNT5A, WNT11 and WNT3A have been shown to
promote migration and invasion of breast cancer cell
lines in vitro and in vivo [43–45]. MB-MDA-231 cell
line xenografts overexpressing secreted Frizzled-related
protein 1, a Wnt pathway inhibitor, produced fewer
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Figure 5. The actin cytoskeleton and fibronectin matrix are rearranged in the absence of FZD6, and exogenous fibronectin rescues the
actin phenotype and invasive potential of MDA-MB-231 cells. (A) Images showing expression of the fibronectin matrix (red) in the
control (scrambled) or FZD6-depleted (Sh1 and Sh2) cell lines. Nuclei were stained with 4′,6-diamidino-2-phenylindole (DAPI) (blue). (B)
Quantification of the experiment shown in (A). The fibronectin fluorescence relative to DAPI was quantified with imaging software. Error
bars indicate SEs, and asterisks indicate statistical significance (student’s t-test). (C) Assembly of F-actin fibres in control (scrambled) or
FZD6-depleted MDA-MB-231 (Sh1) cells was detected by confocal microscopy with phalloidin, to visualize actin, and DRAQ5, to visualize
nuclei. Fibronectin was also assessed by confocal microscopy and two phenotypes were noted: dispersed in control cells, and dots/blobs
in the absence of FZD6 expression. Bar plots on the right side of the panel show quantification of the fibronectin and actin changes. (D)
FZD6-depleted MDA-MB-231 cells were exposed to exogenous fibronectin for the indicated times, and subjected to confocal analysis to
detect the actin cytoskeleton. Quantification is shown in the bar plot. Confocal data are expressed as percentages of total, as means± SEs
of three independent experiments, with at least 100 cells quantified per experiment. ***p< 0.01, **p< 0.01 and *p< 0.05 as compared
with control untreated cells (Student’s t-test). (E) In vitro invasion assay showing rescue of EGF-mediated invasion in FZD6-depleted (Sh1)
but not in control (scrambled) MDA-MB231 cell lines exposed to exogenous fibronectin. Error bars indicate SEs, and the asterisk indicates
statistical significance (p= 0.0477, Student’s t-test). (F) GST pull-down/western blot analysis to detect active forms of Rho in MDA-MB-231
cells infected with control (SCR) or FZD6 (Sh1 and Sh2) shRNAs. Western blotting was carried out with antibodies recognizing FZD6 or Rho
proteins, as indicated. (G) Densitometric quantification of active Rho in three independent pull-down experiments as shown in (F). Error
bars indicate average values± standard error of the mean (SEM), and asterisks indicate statistical significance (***p< 0.0001, **p< 0.0088,
Student’s t-test).
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Figure 6. FZD6 protein expression in breast cancer biopsies predicts distant metastasis. (A, B) Immunohistochemical analysis showing
membranous expression of FZD6 in two invasive human TNBCs. (C, D) Enlargement of the areas indicated by red squares in (A) and
(B), respectively, showing FZD6-positive tumour cells invading a vessel and infiltrating the fibroadipose tissue. Scale bars: 20 μm. (E)
Kaplan–Meier estimates of DFS, local relapse-free survival (LRFS) and DRFS in breast cancer cases from the Italian cohort with (green solid
line) or without (blue dashed line) expression of FZD6 in the cell membrane as assessed by immunohistochemistry. Statistical significance
was assessed with the log-rank test. Numbers at risk are indicated in the table in the bottom of the panel. (F) Graphs were obtained with the
Kaplan–Meier plotter (kmplotter.com) selecting lymph node-negative patients and the autoselect best cut-off option. Red lines indicate
high FZD6 expression, and black lines indicate low FZD6 expression. Statistical significance was assessed with the log-rank test.
metastases in mice than injection with the control cell
line [43]. FZD7 knockdown reduces canonical Wnt sig-
nalling, tumour cell proliferation and invasiveness in
breast cancer in vivo [12]. Klemm et al suggested a role
of the β-catenin-independent pathway in breast cancer
brain metastases, and observed substantial increases in
cell invasiveness in the MB-MDA-231 and MCF7 cell
lines after stimulation with WNT5A andWNT5B, with-
out observing β-catenin activation [46]. Furthermore,
Sottnik et al have highlighted the important role of Wnt
signalling in bone metastasis, in keeping with our own
observation of reduced bone metastasis in mice injected
with FZD6-depletedMDA-MB-231 cells [47]. The ther-
apeutic value of eliminating even small percentages of
aggressive cancer clones should not be underestimated,
as demonstrated in the MMTV-PyMT model of breast
cancer, in which knockdown of keratin 14 blocked col-
lective invasion in vitro and in vivo, despite the fact that
only 2% of tumour cells expressed this marker [48].
There is increasing interest in the importance of cell
invasion, motility and reseeding of metastases even after
initial tumour cell dissemination.
Our study corroborates the view that components
of the Wnt/β-catenin-independent signalling pathway
have a key role in regulating cell movement, invasion
and metastasis in breast cancer, opening new diagnostic
and therapeutic opportunities. First, positivity for FZD6
might be used to identify patients with TNBC with a
higher risk of metastatic recurrence who would ben-
efit from an aggressive therapeutic approach. Second,
surface expression of FZD6 could be used to develop
naked or toxin-conjugated therapeutic antibodies to
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target the aggressive breast cancer cell subclones that
are the leaders of collective invasion.
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